JNPMEDI announced on March 22nd that it had signed an MOU with MediRama for the development of clinical trial services for anticancer drugs. The two companies plan to develop clinical medical data solutions specialized in anticancer drugs to strengthen the competitiveness of digital-based clinical services. To this end, they have decided to establish a business cooperation system.
JNPMEDI plans to enhance its service competitiveness by leveraging insights into oncology clinical trials through collaboration with MediRama, composed of clinical experts from global pharmaceutical companies with extensive clinical trial experience. These insights will be integrated into 'Maven Clinical Cloud', aiming to strengthen their service offerings.
"Clinical trials for anticancer drugs require a lot of investment in terms of time and money," said Kwunho Jeong, CEO of JNPMEDI. "We will do our best to develop functions that can increase work efficiency." He further added, "Our collaboration with MediLama is expected to be a significant milestone in advancing JNPMEDI's solution capabilities.”
Hanlim Moon, MD, PhD, and CEO of MediRama, said, "Medirama provides consulting services for optimized clinical plans to collaborators and operates planned clinical trials in the shortest time to maximize win-win (synergy) effects. We will create a case that presents new possibilities in the success of new drug development through collaboration with JNPMEDI."
JNPMEDI announced on March 22nd that it had signed an MOU with MediRama for the development of clinical trial services for anticancer drugs. The two companies plan to develop clinical medical data solutions specialized in anticancer drugs to strengthen the competitiveness of digital-based clinical services. To this end, they have decided to establish a business cooperation system.
JNPMEDI plans to enhance its service competitiveness by leveraging insights into oncology clinical trials through collaboration with MediRama, composed of clinical experts from global pharmaceutical companies with extensive clinical trial experience. These insights will be integrated into 'Maven Clinical Cloud', aiming to strengthen their service offerings.
"Clinical trials for anticancer drugs require a lot of investment in terms of time and money," said Kwunho Jeong, CEO of JNPMEDI. "We will do our best to develop functions that can increase work efficiency." He further added, "Our collaboration with MediLama is expected to be a significant milestone in advancing JNPMEDI's solution capabilities.”
Hanlim Moon, MD, PhD, and CEO of MediRama, said, "Medirama provides consulting services for optimized clinical plans to collaborators and operates planned clinical trials in the shortest time to maximize win-win (synergy) effects. We will create a case that presents new possibilities in the success of new drug development through collaboration with JNPMEDI."